Estudo de segurança e determinação de dose de neratinibe em crianças e adultos jovens com câncer que retornaram ou não responderam ao tratamento
Um Estudo de Fase I/II de Neratinibe em Pacientes Pediátricos com Tumores Sólidos Recidivantes ou Refratários
The purpose of this study is to test the safety of neratinib at different dose levels and to find out what effects, good and bad, it has on the patients and the cancer.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Alberta
-
Calgary, Alberta, Canadá, T3B 6A8
- Alberta Children'S Hospital
-
-
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85016
- Phoenix Children'S Hospital
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72206
- Arkansas Children's Hospital
-
-
California
-
Palo Alto, California, Estados Unidos, 94304
- Stanford University School of Medicine and Stanford Cancer Institute
-
-
Florida
-
Orlando, Florida, Estados Unidos, 32806
- Arnold Palmer Hospital for Children
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Pennsylvania
-
Hershey, Pennsylvania, Estados Unidos, 17033
- Pennsylvania State Hershey Children's Hospital
-
-
Texas
-
San Antonio, Texas, Estados Unidos, 78229
- University of Texas
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84113
- Huntsman Cancer Institue
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Diagnosis: Pathologic confirmation of solid tumor, including central nervous system tumor or lymphoma.
-
Recurrent or Refractory Disease for which no further effective standard treatment is available.
-
Patient must have failed at least one prior therapy.
-
All patients must have evaluable disease as defined as:
- Solid tumors must have a lesion evaluable by RECIST criteria version 1.1;
- Central nervous system tumors will be evaluated by RANO criteria.
-
Available tissue to perform protein and genomic analysis
-
Age:
- Phase 1: ≥ 3 and ≤ 21 years of age at time of enrollment
- Phase 2: ≥ 3 and ≤ 21 years of age at diagnosis
-
Body Surface Area requirements varied by dose level:
Dose Level BSA (m2)
-
1 ≥ 0.82
- ≥ 0.66
- ≥ 0.52
- ≥ 0.45
-
Performance level:
- Lansky score ≥ 60% (patients < 16 years of age)
- Karnofsky score ≥ 60% (patients ≥ 16 years of age)
-
Cardiac Function: Patients must have a shortening fraction ≥ 27% or left ventricular ejection fraction ≥ 50% measured by echocardiogram (ECHO) or measured by multiple-gated acquisition scans (MUGA).
-
Negative β-human chorionic gonadotropin (hCG) pregnancy test for female patients of child-bearing potential ≤ 7 days before starting neratinib therapy.
-
Female patients of reproductive potential must agree and commit to the use of a highly effective method of contraception, as determined to be acceptable by the investigator, from the time of informed consent until 28 days after the last dose of the investigational product. Male patients must agree and commit to use a barrier method of contraception while on treatment and for 3 months after the last dose of the investigational product.
-
Written informed consent/assent prior to any study-specific procedures.
-
Patient must be able to swallow tablet or have existing gastrostomy feeding tube to enable administration of tablet.
-
Patients must have recovered from the acute toxic effects of all prior therapy to ≤ grade 1 before entering this study.
Exclusion Criteria:
-
Prior treatment within the following timeframes:
- Systemic chemotherapy or biologic therapy ≤ 2 weeks or 5 half lives (t ½) of the agent used, whichever is shorter, prior to the start of neratinib
- Radiation therapy outside the central nervous system ≤ 14 days prior to neratinib
- Radiation to the central nervous system ≤ 12 weeks prior to initiation of neratinib
-
Patients with previous allogeneic stem cell transplant (SCT) if they meet either of the following criteria:
-
60 days from allogeneic SCT
- Active acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive therapy as treatment for GvHD
-
-
Inadequate marrow function in Cohort 1:
- Absolute neutrophil count < 1.0 x 10^9 /L
- Platelets < 100 x 10^9 /L
- Hemoglobin < 8.0 g/dL (transfusion permitted at least 7 days prior to baseline)
-
Total bilirubin > 1.5 X the upper limit of normal (ULN) for age
-
AST (SGOT) and ALT (SGPT) > 3 X ULN (unless attributed to disease involvement)
-
Serum creatinine > 1.5 X ULN for age or creatinine clearance ≤ 60mL/min/1.73m^2
-
Symptomatic or unstable brain metastases. (Note: Asymptomatic patients with metastatic brain disease who have been on a stable dose of corticosteroids for treatment of brain metastases for at least 14 days (or decreasing dose of corticosteroid) are eligible to participate in the study.) Patients with primary central nervous system tumors are eligible.
-
Clinically active cardiac disease, including prolonged QTc interval ≥ 481ms (i.e. ≥ grade 2)
-
Pregnant or breast-feeding women
-
Being actively treated for a concurrent malignancy with the exception of basal cell carcinoma or carcinoma in situ of the cervix.
-
Uncontrolled intercurrent illness including, but not limited to uncontrolled infection, unexplained fever > 38.5°C (101.3°F) or psychiatric illness/social situation that would limit compliance with study requirements.
-
Significant chronic gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption, or Grade ≥ 2 National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events Version 4.0 [CTCAE v.4.0] diarrhea of any etiology at baseline).
-
Known history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related disease
-
Known history of hepatitis C or known active hepatitis B infection
-
Known hypersensitivity to any component of the investigational product
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Neratinib
There are 2 parts to this study: a Phase I part and a Phase II part. The Phase I portion is known as the dose escalation phase where neratinib will be tested in groups of 3-6 patients to establish the maximum tolerated dose (MTD). The phase II portion will determine whether the MTD shows a response to the tumor. |
Neratinib will be administered orally, or through existing gastrostomy feeding tube, once a day with food, preferably in the morning, continuously for 28-day cycles, with no rest between cycles. Dose will be scaled by body surface area (BSA). |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
the number of patients who have experienced Dose Limiting Toxicity
Prazo: 1 year
|
NCI CTCAE Version 4.0.Definition of Hematologic Dose-Limiting Toxicity (solid tumor cohort only) Any hematologic toxicity as indicated: Febrile neutropenia defined as Grade 3 or 4 neutropenia with fever ≥ 38.5°C and /or infection requiring antibiotic or antifungal treatment Grade 4 neutropenia lasting > 7 days Grade 4 thrombocytopenia lasting > 7days Any drug-related adverse experience, regardless of grade, leading to a dose reduction of a study drug. Non-Hematologic Dose-Limiting Toxicities: Non-hematologic dose-limiting toxicity will be defined as any Grade 3, 4 or 5 nonhematologic toxicity with the specific exception of: Any grade diarrhea that occurs in the setting of poor compliance with supportive measures that last for < 48 hours Any grade dehydration related to diarrhea that occurs in the setting of inadequate compliance to supportive care measures that last for < 48 hours. |
1 year
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimado)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do Sistema Nervoso
- Processos Patológicos
- Neoplasias por local
- Neoplasias
- Atributos da doença
- Doenças do sistema imunológico
- Neoplasias por Tipo Histológico
- Doenças Hematológicas
- Doenças Linfáticas
- Distúrbios Linfoproliferativos
- Distúrbios imunoproliferativos
- Neoplasias do Sistema Nervoso
- Condições Patológicas, Sinais e Sintomas
- Doenças hemic e linfáticas
- Recorrência
- Leucemia
- Doença
- Linfoma
- Neoplasias do Sistema Nervoso Central
- Neratinibe
Outros números de identificação do estudo
Outros números de identificação do estudo
- 16-878
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .